<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD06410000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P37840</UniProt_ID>
  <Seq_Length>140</Seq_Length>
  <Molecule_Weight>14460</Molecule_Weight>
  <KEGG_ID>hsa:6622</KEGG_ID>
  <Orthology_ID>K04528</Orthology_ID>
  <EBI_ID>EBI-985879</EBI_ID>
  <Function_Summary>May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.</Function_Summary>
  <Pfam_ID>PF01387:Synuclein</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Non-A4 component of amyloid precursor</Alias>
      <Alias>Non-A beta component of AD amyloid</Alias>
      <Alias>NACP</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the microtubule constituent protein alpha-tubulin.</Detail>
      <Keyword>Alpha-tubulin binding</Keyword>
      <Ontology_ID>GO:0043014</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with tau protein. tau is a microtubule-associated protein, implicated in Alzheimer's disease, Down Syndrome and ALS.</Detail>
      <Keyword>Tau protein binding</Keyword>
      <Ontology_ID>GO:0048156</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.</Detail>
      <Keyword>Oxidoreductase activity</Keyword>
      <Ontology_ID>GO:0016491</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein or proteins.</Detail>
      <Keyword>Identical protein binding</Keyword>
      <Ontology_ID>GO:0042802</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with calcium ions (Ca2+).</Detail>
      <Keyword>Calcium ion binding</Keyword>
      <Ontology_ID>GO:0005509</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with dynein, the multisubunit protein complex that is associated with microtubules.</Detail>
      <Keyword>Dynein binding</Keyword>
      <Ontology_ID>GO:0045502</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with copper (Cu) ions.</Detail>
      <Keyword>Copper ion binding</Keyword>
      <Ontology_ID>GO:0005507</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a phosphorylated protein.</Detail>
      <Keyword>Phosphoprotein binding</Keyword>
      <Ontology_ID>GO:0051219</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Stops, prevents or reduces the activity of a caspase, any of a group of cysteine proteases involved in apoptosis.</Detail>
      <Keyword>Caspase inhibitor activity</Keyword>
      <Ontology_ID>GO:0043027</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently and stoichiometrically with kinesin, a member of a superfamily of microtubule-based motor proteins that perform force-generating tasks such as organelle transport and chromosome segregation.</Detail>
      <Keyword>Kinesin binding</Keyword>
      <Ontology_ID>GO:0019894</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with Hsp70 proteins, any of a group of heat shock proteins around 70kDa in size.</Detail>
      <Keyword>Hsp70 protein binding</Keyword>
      <Ontology_ID>GO:0030544</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ferrous iron, Fe(II).</Detail>
      <Keyword>Ferrous iron binding</Keyword>
      <Ontology_ID>GO:0008198</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with magnesium (Mg) ions.</Detail>
      <Keyword>Magnesium ion binding</Keyword>
      <Ontology_ID>GO:0000287</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a histone, any of a group of water-soluble proteins found in association with the DNA of plant and animal chromosomes. They are involved in the condensation and coiling of chromosomes during cell division and have also been implicated in nonspecific suppression of gene activity.</Detail>
      <Keyword>Histone binding</Keyword>
      <Ontology_ID>GO:0042393</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>30</Position>
      <Original>Ala</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>46</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>53</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of dopamine into a cell.</Detail>
      <Keyword>Negative regulation of dopamine uptake</Keyword>
      <Ontology_ID>GO:0051585</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of receptor recycling.</Detail>
      <Keyword>Positive regulation of receptor recycling</Keyword>
      <Ontology_ID>GO:0001921</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Upregulation of the activity of a caspase, any of a group of cysteine proteases involved in apoptosis.</Detail>
      <Keyword>Activation of caspase activity</Keyword>
      <Ontology_ID>GO:0006919</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of thrombin receptor protein signaling pathway activity. A thrombin receptor signaling pathway is the series of molecular signals generated as a consequence of a thrombin receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Negative regulation of thrombin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0070495</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus.</Detail>
      <Keyword>Response to interleukin-1</Keyword>
      <Ontology_ID>GO:0070555</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.</Detail>
      <Keyword>Positive regulation of release of sequestered calcium ion into cytosol</Keyword>
      <Ontology_ID>GO:0051281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.</Detail>
      <Keyword>Dopamine biosynthetic process</Keyword>
      <Ontology_ID>GO:0042416</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An endocytosis process that results in the invagination of the axonal plasma membrane to create a membrane-bounded vesicle. This process takes up excess membrane that would otherwise accumulate at the presynaptic terminal due to fusion of vesicle membranes during neurotransmitter release. The vesicles created may subsequently be used for neurotransmitter storage and release.</Detail>
      <Keyword>Synaptic vesicle endocytosis</Keyword>
      <Ontology_ID>GO:0048488</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid.</Detail>
      <Keyword>Regulation of phospholipase activity</Keyword>
      <Ontology_ID>GO:0010517</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency or extent of inositol phosphate biosynthesis. Inositol phosphate biosynthetic processes are the chemical reactions and pathways resulting in the formation of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.</Detail>
      <Keyword>Positive regulation of inositol phosphate biosynthetic process</Keyword>
      <Ontology_ID>GO:0060732</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnesium ion stimulus.</Detail>
      <Keyword>Response to magnesium ion</Keyword>
      <Ontology_ID>GO:0032026</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon-gamma is also known as type II interferon.</Detail>
      <Keyword>Response to interferon-gamma</Keyword>
      <Ontology_ID>GO:0034341</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of serotonin into a cell.</Detail>
      <Keyword>Negative regulation of serotonin uptake</Keyword>
      <Ontology_ID>GO:0051612</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(II) ion stimulus.</Detail>
      <Keyword>Response to iron(II) ion</Keyword>
      <Ontology_ID>GO:0010040</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a copper ion stimulus.</Detail>
      <Keyword>Cellular response to copper ion</Keyword>
      <Ontology_ID>GO:0071280</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of endocytosis.</Detail>
      <Keyword>Positive regulation of endocytosis</Keyword>
      <Ontology_ID>GO:0045807</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of norepinephrine into a cell.</Detail>
      <Keyword>Negative regulation of norepinephrine uptake</Keyword>
      <Ontology_ID>GO:0051622</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the platelet-derived growth factor receptor signaling pathway.</Detail>
      <Keyword>Negative regulation of platelet-derived growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0010642</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of microtubule polymerization.</Detail>
      <Keyword>Negative regulation of microtubule polymerization</Keyword>
      <Ontology_ID>GO:0031115</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the regulated release of dopamine.</Detail>
      <Keyword>Regulation of dopamine secretion</Keyword>
      <Ontology_ID>GO:0014059</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A receptor-mediated endocytosis process that results in the movement of receptors from the plasma membrane to the inside of the cell. The process begins when cell surface receptors are monoubiquitinated following ligand-induced activation; receptors are subsequently taken up into endocytic vesicles and targeted to the lysosome or vacuole for degradation. Receptor internalization serves as a mechanism to downregulate receptor signaling.</Detail>
      <Keyword>Receptor internalization</Keyword>
      <Ontology_ID>GO:0031623</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of fibrils, extracellular matrix material consisting of polysaccharides and protein.</Detail>
      <Keyword>Fibril organization</Keyword>
      <Ontology_ID>GO:0043206</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of protein serine/threonine kinase activity.</Detail>
      <Keyword>Positive regulation of protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0071902</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process which directly inhibits any of the steps required for cell death by apoptosis.</Detail>
      <Keyword>Anti-apoptosis</Keyword>
      <Ontology_ID>GO:0006916</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation.</Detail>
      <Keyword>Protein destabilization</Keyword>
      <Ontology_ID>GO:0031648</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-serine.</Detail>
      <Keyword>Positive regulation of peptidyl-serine phosphorylation</Keyword>
      <Ontology_ID>GO:0033138</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops or reduces the activity of a monooxygenase.</Detail>
      <Keyword>Negative regulation of monooxygenase activity</Keyword>
      <Ontology_ID>GO:0032769</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.</Detail>
      <Keyword>Response to lipopolysaccharide</Keyword>
      <Ontology_ID>GO:0032496</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of exocytosis.</Detail>
      <Keyword>Negative regulation of exocytosis</Keyword>
      <Ontology_ID>GO:0045920</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A biological process that results in permanent cessation of all vital functions of a cell.</Detail>
      <Keyword>Cell death</Keyword>
      <Ontology_ID>GO:0008219</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of an acetyl group to a histone protein.</Detail>
      <Keyword>Negative regulation of histone acetylation</Keyword>
      <Ontology_ID>GO:0035067</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops or reduces the activity of a transporter.</Detail>
      <Keyword>Negative regulation of transporter activity</Keyword>
      <Ontology_ID>GO:0032410</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epinephrine stimulus. Epinephrine is a catecholamine that has the formula C9H13NO3; it is secreted by the adrenal medulla to act as a hormone, and released by certain neurons to act as a neurotransmitter active in the central nervous system.</Detail>
      <Keyword>Cellular response to epinephrine stimulus</Keyword>
      <Ontology_ID>GO:0071872</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of dopamine into a cell, typically presynaptic neurons or glial cells. Dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.</Detail>
      <Keyword>Dopamine uptake</Keyword>
      <Ontology_ID>GO:0051583</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>87</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>129</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>129</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>125</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA</Protein_Seq>
    <DNA_Seq>AGGAGAAGGAGAAGGAGGAGGACTAGGAGGAGGAGGACGGCGACGACCAGAAGGGGCCCAAGAGAGGGGGCGAGCGACCGAGCGCCGCGACGCGGAAGTGAGGTGCGTGCGGGCTGCAGCGCAGACCCCGGCCCGGCCCCTCCGAGAGCGTCCTGGGCGCTCCCTCACGCCTTGCCTTCAAGCCTTCTGCCTTTCCACCCTCGTGAGCGGAGAACTGGGAGTGGCCATTCGACGACAGTGTGGTGTAAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCTGAGAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTCCAAAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAATGTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGAGCAGGGAGCATTGCAGCAGCCACTGGCTTTGTCAAAAAGGACCAGTTGGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGAAGATATGCCTGTGGATCCTGACAATGAGGCTTATGAAATGCCTTCTGAGGAAGGGTATCAAGACTACGAACCTGAAGCCTAAGAAATATCTTTGCTCCCAGTTTCTTGAGATCTGCTGACAGATGTTCCATCCTGTACAAGTGCTCAGTTCCAATGTGCCCAGTCATGACATTTCTCAAAGTTTTTACAGTGTATCTCGAAGTCTTCCATCAGCAGTGATTGAAGTATCTGTACCTGCCCCCACTCAGCATTTCGGTGCTTCCCTTTCACTGAAGTGAATACATGGTAGCAGGGTCTTTGTGTGCTGTGGATTTTGTGGCTTCAATCTACGATGTTAAAACAAATTAAAAACACCTAAGTGACTACCACTTATTTCTAAATCCTCACTATTTTTTTGTTGCTGTTGTTCAGAAGTTGTTAGTGATTTGCTATCATATATTATAAGATTTTTAGGTGTCTTTTAATGATACTGTCTAAGAATAATGACGTATTGTGAAATTTGTTAATATATATAATACTTAAAAATATGTGAGCATGAAACTATGCACCTATAAATACTAAATATGAAATTTTACCATTTTGCGATGTGTTTTATTCACTTGTGTTTGTATATAAATGGTGAGAATTAAAATAAAACGTTATCTCATTGCAAAAATATTTTATTTTTATCCCATCTCACTTTAATAATAAAAATCATGCTTATAAGCAACATGAATTAAGAACTGACACAAAGGACAAAAATATAAAGTTATTAATAGCCATTTGAAGAAGGAGGAATTTTAGAAGAGGTAGAGAAAATGGAACATTAACCCTACACTCGGAATTCCCTGAAGCAACACTGCCAGAAGTGTGTTTTGGTATGCACTGGTTCCTTAAGTGGCTGTGATTAATTATTGAAAGTGGGGTGTTGAAGACCCCAACTACTATTGTAGAGTGGTCTATTTCTCCCTTCAATCCTGTCAATGTTTGCTTTACGTATTTTGGGGAACTGTTGTTTGATGTGTATGTGTTTATAATTGTTATACATTTTTAATTGAGCCTTTTATTAACATATATTGTTATTTTTGTCTCGAAATAATTTTTTAGTTAAAATCTATTTTGTCTGATATTGGTGTGAATGCTGTACCTTTCTGACAATAAATAATATTCGACCATGAATAAAAAAAAAAAAAAAGTGGGTTCCCGGGAACTAAGCAGTGTAGAAGATGATTTTGACTACACCCTCCTTAGAGAGCCATAAGACACATTAGCACATATTAGCACATTCAAGGCTCTGAGAGAATGTGGTTAACTTTGTTTAACTCAGCATTCCTCACTTTTTTTTTTTAATCATCAGAAATTCTCTCTCTCTCTCTCTCTTTTTCTCTCGCTCTCTTTTTTTTTTTTTTTTTACAGGAAATGCCTTTAAACATCGTTGGAACTACCAGAGTCACCTTAAAGGAGATCAATTCTCTAGACTGATAAAAATTTCATGGCCTCCTTTAAATGTTGCCAAATATATGAATTCTAGGATTTTTCCTTAGGAAAGGTTTTTCTCTTTCAGGGAAGATCTATTAACTCCCCATGGGTGCTGAAAATAAACTTGATGGTGAAAAACTCTGTATAAATTAATTTAAAAATTATTTGGTTTCTCTTTTTAATTATTCTGGGGCATAGTCATTTCTAAAAGTCACTAGTAGAAAGTATAATTTCAAGACAGAATATTCTAGACATGCTAGCAGTTTATATGTATTCATGAGTAATGTGATATATATTGGGCGCTGGTGAGGAAGGAAGGAGGAATGAGTGACTATAAGGATGGTTACCATAGAAACTTCCTTTTTTACCTAATTGAAGAGAGACTACTACAGAGTGCTAAGCTGCATGTGTCATCTTACACTAGAGAGAAATGGTAAGTTTCTTGTTTTATTTAAGTTATGTTTAAGCAAGGAAAGGATTTGTTATTGAACAGTATATTTCAGGAAGGTTAGAAAGTGGCGGTTAGGATATATTTTAAATCTACCTAAAGCAGCATATTTTAAAAATTTAAAAGTATTGGTATTAAATTAAGAAATAGAGGACAGAACTAGACTGATAGCAGTGACCTAGAACAATTTGAGATTAGGAAAGTTGTGACCATGAATTTAAGGATTTATGTGGATACAAATTCTCCTTTAAAGTGTTTCTTCCCTTAATATTTATCTGACGGTAATTTTTGAGCAGTGAATTACTTTATATATCTTAATAGTTTATTTGGGACCAAACACTTAAACAAAAAGTTCTTTAAGTCATATAAGCCTTTTCAGGAAGCTTGTCTCATATTCACTCCCGAGACATTCACCTGCCAAGTGGCCTGAGGATCAATCCAGTCCTAGGTTTATTTTGCAGACTTACATTCTCCCAAGTTATTCAGCCTCATATGACTCCACGGTCGGCTTTACCAAAACAGTTCAGAGTGCACTTTGGCACACAATTGGGAACAGAACAATCTAATGTGTGGTTTGGTATTCCAAGTGGGGTCTTTTTCAGAATCTCTGCACTAGTGTGAGATGCAAACATGTTTCCTCATCTTTCTGGCTTATCCAGTATGTAGCTATTTGTGACATAATAAATATATACATATATGAAAATA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Presynaptic nerve terminals</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Brain</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell junction</CellLocal>
      <Ontology_ID>GO:0030054</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Fibril</CellLocal>
      <Ontology_ID>GO:0043205</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Actin cytoskeleton</CellLocal>
      <Ontology_ID>GO:0015629</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Axon</CellLocal>
      <Ontology_ID>GO:0030424</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Synapse</CellLocal>
      <Ontology_ID>GO:0045202</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell cortex</CellLocal>
      <Ontology_ID>GO:0005938</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Growth cone</CellLocal>
      <Ontology_ID>GO:0030426</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Inclusion body</CellLocal>
      <Ontology_ID>GO:0016234</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Amyloid</CellLocal>
      <Ontology_ID>KW-0034</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Perinuclear region of cytoplasm</CellLocal>
      <Ontology_ID>GO:0048471</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>SNCA</Gene_Name>
    <Gene_Alias>NACP; PARK1</Gene_Alias>
    <Gene_ID>6622</Gene_ID>
    <Genbank_ACCN>NM_000345</Genbank_ACCN>
    <Protein_ACCN>NP_000336</Protein_ACCN>
    <HGNC_ID>11138</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/6622</Gene_URL>
    <UCSC_ID>uc010ikt.3</UCSC_ID>
    <EMBL_ID>ENSG00000145335</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P37840</Uniprot_ID>
      <Gene_Name>SNCA</Gene_Name>
      <EBI_ID>EBI-985879</EBI_ID>
      <PPI_EBI_URL>EBI-985879,EBI-985879</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Parkinson's Disease</Disease_Name>
      <Disease_Detail>Parkinson's Disease</Disease_Detail>
      <Disease_DB>PRK002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/parkinsons_disease?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysautonomia</Disease_Name>
      <Disease_Detail>Dysautonomia</Disease_Detail>
      <Disease_DB>DYS021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysautonomia?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuroblastoma</Disease_Name>
      <Disease_Detail>Neuroblastoma</Disease_Detail>
      <Disease_DB>NRB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroblastoma?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pure Autonomic Failure</Disease_Name>
      <Disease_Detail>Pure Autonomic Failure</Disease_Detail>
      <Disease_DB>PRT058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pure_autonomic_failure?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Corticobasal Degeneration</Disease_Name>
      <Disease_Detail>Corticobasal Degeneration</Disease_Detail>
      <Disease_DB>CRT033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/corticobasal_degeneration?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Striatonigral Degeneration</Disease_Name>
      <Disease_Detail>Striatonigral Degeneration</Disease_Detail>
      <Disease_DB>STR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/striatonigral_degeneration?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuroaxonal Dystrophy</Disease_Name>
      <Disease_Detail>Neuroaxonal Dystrophy</Disease_Detail>
      <Disease_DB>NRX001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroaxonal_dystrophy?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Snca-Related Parkinson Disease</Disease_Name>
      <Disease_Detail>Snca-Related Parkinson Disease</Disease_Detail>
      <Disease_DB>SNC002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/snca_related_parkinson_disease?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rem Sleep Behavior Disorder</Disease_Name>
      <Disease_Detail>Rem Sleep Behavior Disorder</Disease_Detail>
      <Disease_DB>RMS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rem_sleep_behavior_disorder?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tremor</Disease_Name>
      <Disease_Detail>Tremor</Disease_Detail>
      <Disease_DB>TRM003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tremor?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Synucleinopathy</Disease_Name>
      <Disease_Detail>Synucleinopathy</Disease_Detail>
      <Disease_DB>SYN058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/synucleinopathy?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lewy Body Dementia</Disease_Name>
      <Disease_Detail>Lewy Body Dementia</Disease_Detail>
      <Disease_DB>LWY001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lewy_body_dementia?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Movement Disease</Disease_Name>
      <Disease_Detail>Movement Disease</Disease_Detail>
      <Disease_DB>MVM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/movement_disease?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dementia</Disease_Name>
      <Disease_Detail>Dementia</Disease_Detail>
      <Disease_DB>DMN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dementia?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fahr's Syndrome</Disease_Name>
      <Disease_Detail>Fahr's Syndrome</Disease_Detail>
      <Disease_DB>FHR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fahrs_syndrome?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Essential Tremor</Disease_Name>
      <Disease_Detail>Essential Tremor</Disease_Detail>
      <Disease_DB>ESS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/essential_tremor?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Frontotemporal Dementia</Disease_Name>
      <Disease_Detail>Frontotemporal Dementia</Disease_Detail>
      <Disease_DB>FRN006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/frontotemporal_dementia?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transthyretin Amyloidosis</Disease_Name>
      <Disease_Detail>Transthyretin Amyloidosis</Disease_Detail>
      <Disease_DB>TRN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transthyretin_amyloidosis?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuronal Intranuclear Inclusion Disease</Disease_Name>
      <Disease_Detail>Neuronal Intranuclear Inclusion Disease</Disease_Detail>
      <Disease_DB>NRN008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuronal_intranuclear_inclusion_disease?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Parkinson Disease 4</Disease_Name>
      <Disease_Detail>Parkinson's Disease</Disease_Detail>
      <Disease_DB>PRK030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/parkinson_disease_4?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Parkinson Disease 1</Disease_Name>
      <Disease_Detail>Parkinson's Disease</Disease_Detail>
      <Disease_DB>PRK031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/parkinson_disease_1?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Argyrophilic Grain Disease</Disease_Name>
      <Disease_Detail>Argyrophilic Grain Disease</Disease_Detail>
      <Disease_DB>ARG005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/argyrophilic_grain_disease?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Parkinson Disease 15, Autosomal Recessive</Disease_Name>
      <Disease_Detail>Parkinson's Disease</Disease_Detail>
      <Disease_DB>PRK027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/parkinson_disease_15_autosomal_recessive?search=SNCA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multiple System Atrophy</Disease_Name>
      <Disease_Detail>Multiple System Atrophy</Disease_Detail>
      <Disease_DB>MLT021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multiple_system_atrophy?search=SNCA#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Human micelle-bound alpha-synuclein</PDB_Title>
      <PDB_ID>1XQ8</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XQ8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and dynamics of micelle-bound human alpha-synuclein</PubMed_Title>
      <Author>Ulmer, T.S., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:9595-9603</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15615727?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cyrstal structure of human alpha-synuclein (10-42) fused to maltose binding protein (MBP)</PDB_Title>
      <PDB_ID>3Q26</PDB_ID>
      <Resolution>1.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q26</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of segments of alpha-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation</PubMed_Title>
      <Author>Zhao, M., et al.</Author>
      <Journal>Protein Sci.(2011)20:996-1004</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21462277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cyrstal structure of human alpha-synuclein (58-79) fused to maltose binding protein (MBP)</PDB_Title>
      <PDB_ID>3Q28</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q28</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of segments of alpha-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation</PubMed_Title>
      <Author>Zhao, M., et al.</Author>
      <Journal>Protein Sci.(2011)20:996-1004</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21462277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human alpha-synuclein (1-19) fused to maltose binding protein (MBP)</PDB_Title>
      <PDB_ID>3Q25</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q25</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of segments of alpha-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation</PubMed_Title>
      <Author>Zhao, M., et al.</Author>
      <Journal>Protein Sci.(2011)20:996-1004</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21462277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cyrstal structure of human alpha-synuclein (32-57) fused to maltose binding protein (MBP)</PDB_Title>
      <PDB_ID>3Q27</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q27</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of segments of alpha-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation</PubMed_Title>
      <Author>Zhao, M., et al.</Author>
      <Journal>Protein Sci.(2011)20:996-1004</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21462277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF A SINGLE DOMAIN CAMELID ANTIBODY FRAGMENT IN COMPLEX WITH A C-TERMINAL PEPTIDE OF ALPHA-SYNUCLEIN</PDB_Title>
      <PDB_ID>2X6M</PDB_ID>
      <Resolution>1.62</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2X6M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Properties of a Complex of Alpha-Synuclein and a Single-Domain Camelid Antibody.</PubMed_Title>
      <Author>De Genst, E.J., et al.</Author>
      <Journal>J.Mol.Biol.(2010)402:326</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20620148?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cyrstal structure of human alpha-synuclein (1-19) fused to maltose binding protein (MBP)</PDB_Title>
      <PDB_ID>3Q29</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q29</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of segments of alpha-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation</PubMed_Title>
      <Author>Zhao, M., et al.</Author>
      <Journal>Protein Sci.(2011)20:996-1004</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21462277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of a Dodecapeptide from Alpha-Synuclein Bound with Synphilin-1</PDB_Title>
      <PDB_ID>2JN5</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JN5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication.</PubMed_Title>
      <Author>Xie, Y.Y., et al.</Author>
      <Journal>Faseb J.(2010)24:196-205</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19762560?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SLAS-micelle bound alpha-synuclein</PDB_Title>
      <PDB_ID>2KKW</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KKW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins.</PubMed_Title>
      <Author>Rao, J.N., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:8657-8668</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20524659?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05012</Pathway_ID>
      <Pathway_Title>Parkinson's disease</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Neurodegenerative diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05010</Pathway_ID>
      <Pathway_Title>Alzheimer's disease</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Neurodegenerative diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Coiled coil proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.i.h.b.b.b.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1xq8</CATH_URL>
  </Fold>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>